Hello, Sign in
My Account
My Account
New customer? Start here
| Catalog # | Availability | Size | Quantity | Unit Price | Save For Later Wish List | |
|---|---|---|---|---|---|---|
| HRM0007-5 | 7 days | 5 mg | $120.00 |
Select product before adding to cart
|
||
| HRM0007-20 | 7 days | 20 mg | $290.00 | |||
| HRM0007-100 | 7 days | 100 mg | $800.00 |
Product Overview | |
| Name | Bremelanotide |
|---|---|
| Description | |
| Bremelanotide | |
| Synonyms | |
| PT-141, Rekynda, bremelanotide acetate. | |
| Physical Appearance | |
| Sterile Filtered White lyophilized (freeze-dried) powder. | |
| Formulation | |
| The protein was lyophilized with no additives. | |
| Stability | |
| Lyophilized Bremelanotide although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution Bremelanotide should be stored at 4°C between 2-7 days and for future use below -18°C. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Please prevent freeze-thaw cycles. | |
| Purity | |
| Greater than 97.0% as determined by analysis by RP-HPLC. | |
| Amino acid sequence | |
| Ac-Nle-cyclo(-Asp-His-D-Phe-Arg-Trp-Lys)-OH. | |
| Solubility | |
| It is recommended to reconstitute the lyophilized Bremelanotide in sterile 18MΩ-cm H 2 O not less than 100 µg/ml, which can then be further diluted to other aqueous solutions. | |
| Background | |
| Bremelanotide (PT-141), a synthetic heptapeptide, is a novel therapeutic agent primarily utilized for the treatment of sexual dysfunction. This paper provides an exhaustive review of Bremelanotide, detailing its biochemical structure, mechanism of action, therapeutic applications, and future prospects in clinical medicine. Bremelanotide (PT-141), derived from Melanotan II, is a synthetic peptide developed for its role in treating sexual dysfunction in both men and women (Clayton et al., 2016). This paper presents a comprehensive examination of Bremelanotide, its biological properties, and potential therapeutic uses. Bremelanotide acts as a non-selective agonist of the melanocortin receptors, primarily MC3R and MC4R, present in the central nervous system. The peptide initiates its action in the hypothalamus, leading to downstream effects on sexual desire and arousal (King et al., 2007). The US Food and Drug Administration approved Bremelanotide for the treatment of premenopausal women with hypoactive sexual desire disorder (HSDD) in 2019. In clinical trials, it demonstrated efficacy in enhancing sexual desire and reducing distress associated with HSDD (Kingsberg et al., 2019). While the current focus of Bremelanotide is on treating sexual dysfunction, its future potential may extend to other areas due to its unique mechanism of action. Further research is needed to explore the full therapeutic potential of this intriguing peptide. In conclusion, Bremelanotide represents a significant advance in sexual dysfunction therapeutics, with potential implications extending beyond this realm. | |
| Precautions | |
| Bremelanotide is for research use only and not for use in diagnostic or therapeutic procedures. | |
Background |
Bremelanotide (PT-141), a synthetic heptapeptide, is a novel therapeutic agent primarily utilized for the treatment of sexual dysfunction. This paper provides an exhaustive review of Bremelanotide, detailing its biochemical structure, mechanism of action, therapeutic applications, and future prospects in clinical medicine. Bremelanotide (PT-141), derived from Melanotan II, is a synthetic peptide developed for its role in treating sexual dysfunction in both men and women (Clayton et al., 2016). This paper presents a comprehensive examination of Bremelanotide, its biological properties, and potential therapeutic uses. Bremelanotide acts as a non-selective agonist of the melanocortin receptors, primarily MC3R and MC4R, present in the central nervous system. The peptide initiates its action in the hypothalamus, leading to downstream effects on sexual desire and arousal (King et al., 2007). The US Food and Drug Administration approved Bremelanotide for the treatment of premenopausal women with hypoactive sexual desire disorder (HSDD) in 2019. In clinical trials, it demonstrated efficacy in enhancing sexual desire and reducing distress associated with HSDD (Kingsberg et al., 2019). While the current focus of Bremelanotide is on treating sexual dysfunction, its future potential may extend to other areas due to its unique mechanism of action. Further research is needed to explore the full therapeutic potential of this intriguing peptide. In conclusion, Bremelanotide represents a significant advance in sexual dysfunction therapeutics, with potential implications extending beyond this realm. |
Supporting scientific discovery through quality research products.
ADMEbio is committed to supporting scientific research with high-quality research products and laboratory solutions. We welcome publication submissions from researchers who have used our products in their studies. Your work helps advance scientific discovery and enables us to support the research community.
No publications are currently listed for this product.
Have you used this product in your research?
Submit your publication to help share your work with the scientific community.
Share Your Research
Submit your publications and allow other researchers to discover your work.
Advance Scientific Discovery
Help build a growing body of research that supports the scientific community.
Global Research Community
Your publications contribute to real-world research and innovation.
ADMEbio welcomes feedback from our customers.
Thank you,
ADMEbio Team
